Inventiva (NASDAQ:IVA) Shares Gap Down Following Weak Earnings

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped down prior to trading on Tuesday following a weaker than expected earnings announcement. The stock had previously closed at $5.48, but opened at $5.21. Inventiva shares last traded at $5.4650, with a volume of 223,688 shares changing hands.

The company reported ($0.16) EPS for the quarter. The firm had revenue of $0.01 million for the quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IVA shares. Truist Financial initiated coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price on the stock. Leerink Partners initiated coverage on Inventiva in a research report on Monday, January 12th. They set an “outperform” rating and a $12.00 price objective on the stock. HC Wainwright set a $24.00 price objective on Inventiva and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Barclays assumed coverage on Inventiva in a report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 target price for the company. Finally, UBS Group started coverage on Inventiva in a research note on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $16.56.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IVA. Creative Planning acquired a new stake in shares of Inventiva during the second quarter valued at about $32,000. Virtu Financial LLC acquired a new position in shares of Inventiva in the 4th quarter worth approximately $60,000. XTX Topco Ltd purchased a new position in shares of Inventiva during the 4th quarter worth approximately $84,000. NewEdge Advisors LLC purchased a new position in shares of Inventiva during the 3rd quarter worth approximately $116,000. Finally, Cerity Partners LLC acquired a new stake in Inventiva in the 4th quarter valued at approximately $93,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

The company’s fifty day moving average is $6.24 and its two-hundred day moving average is $5.37.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.